Get started
Author

Elisa Roca

Observed names: E Roca, E. Roca, E., Roca, ELISA ROCA, Roca E, Roca, E., Roca, Elisa
Observed institutions: Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Novartis (Switzerland), Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Hôpital Nord, IRCCS Ospedale San Raffaele, Azienda Ospedaliero-Universitaria "Renato Dulbecco", Fondazione Poliambulanza Istituto Ospedaliero, Henry Dunant Hospital, Ospedale P. Pederzoli – Casa di Cura Privata S.p.a., Vascular Research Center of Marseille, European Institute of Oncology, University of Brescia
ORCID: 0000-0001-7625-7708
Observed ORCID: 0000-0001-7625-7708
OpenAlex ID: A5059014143
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
2020 · Alessandro Russo, Marco Russano, et al. · Advances in Therapy · 169
Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy
2013 · Marco Ravanelli, Davide Farina, et al. · European Radiology · 123
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects
2017 · G Mazziotti, A M Formenti, et al. · European Journal of Endocrinology · 99
PDF
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis
2017 · Elisa Roca, Cristina Gurizzan, et al. · Cancer Treatment Reviews · 86
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
2018 · Francesco Passiglia, Federico Cappuzzo, et al. · British Journal of Cancer · 82
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022 · L. Cantini, G. Mentrasti, et al. · ESMO Open · 69
PDF
CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer
2021 · Giorgio Maria Agazzi, Marco Ravanelli, et al. · La radiologia medica · 63
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
2018 · Mélanie Claps, Fausto Petrelli, et al. · Clinical Genitourinary Cancer · 58
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
2018 · Elisa Roca, Marta Pozzari, et al. · Lung Cancer · 54
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)
2018 · Martina Imbimbo, Margaret Ottaviano, et al. · Cancer Treatment Reviews · 54
PDF
Malignant Pleural Mesothelioma: From the Bench to the Bedside
2012 · P. Astoul, E. Roca, et al. · Respiration · 51
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy
2019 · Marco Ravanelli, Giorgio Maria Agazzi, et al. · La radiologia medica · 50
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
2009 · Monica Giovannini, Vanesa Gregorc, et al. · Journal of Oncology · 50
PDF
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study
2017 · Rebecca Pedersini, Sara Monteverdi, et al. · Bone · 45
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
2022 · Lorenzo Belluomini, Lorenzo Calvetti, et al. · Frontiers in Oncology · 44
PDF
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options
2018 · Soraya Puglisi, Paola Perotti, et al. · Expert Review of Anticancer Therapy · 42
PDF
Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions
2015 · Elisa Roca, Romaric Lacroix, et al. · Oncotarget · 40
PDF
Positive FDG-PET/CT of the Pleura Twenty Years after Talc Pleurodesis: Three Cases of Benign Talcoma
2014 · Thomas Vandemoortele, Sophie Laroumagne, et al. · Respiration · 39
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis
2020 · Massimo Milione, Patrick Maisonneuve, et al. · Neuroendocrinology · 35
PDF
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
2019 · Salvatore Grisanti, on behalf of the Gruppo Neuro-Oncologico Bresciano, et al. · Journal of Neurosurgical Sciences · 35
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2025 · Alessio Cortellini, Leonardo Brunetti, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer
2020 · Giulio Mandelli, Francesco Missale, et al. · Cells · 32
PDF
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer
2017 · Elisa Roca, Alfredo Berruti, et al. · Endocrine Related Cancer · 32
PDF
Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma
2017 · Mélanie Claps, Sara Cerri, et al. · Endocrine · 31
PDF
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
2020 · Marta Laganà, Cristina Gurizzan, et al. · Frontiers in Oncology · 30
PDF
Works count: 121
Citation count: 2,098
H-index: 27
I10-index: 56
Year
Topic
Type